Divis Laboratories on strong growth trend, experts expect margins to expand

Strong demand for active ingredients is further accentuated by shortages even as prospects in custom synthesis business remain firm

Ujjval Jauhari | New Delhi
Last Updated at April 24, 2019 01:23 IST

Lupin to develop Brazil as Latin American manufacturing, export hub

Representative Image

Divis Laboratories is trading near its all-time high and has returned about 38 per cent to investors in the last six months. The firm remains an exporter of generic active pharmaceutical ingredients (about 56 per cent of FY18 revenues) and custom synthesis (CRAMS, about 44 per cent of FY18 revenues). It has continued to benefit from strong demand for both.

TO READ THE FULL STORY, SUBSCRIBE NOW NOW AT JUST RS 249 A MONTH.

MONTHLY

₹ 249

Select

ANNUAL

₹ 1799

Select

Best Offer

SMART ANNUAL

₹ 1499

₹ 1799

Opt for auto renewal and save Rs 300

Select

What you get on Business Standard Premium?

Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
Pick your 5 favourite companies, get a daily email with all news updates on them.
26 years of website archives.
Preferential invites to Business Standard events.